PMID-31968661 – Topical MT-II Suppresses Melanoma via PTEN/AKT Pathway
Wu L et al. "Topical Application of Melanotan-II Suppresses Melanoma through PTEN/AKT/NF-kB/COX-2 Pathway," International Journal of Molecular Sciences, 2020;21(2):681. doi:10.3390/ijms21020681
Quick Reference
| Property | Value |
|---|---|
| PMID | 31968661 |
| DOI | 10.3390/ijms21020681 |
| Year | 2020 |
| Journal | International Journal of Molecular Sciences |
| Study Type | Animal in vivo + In vitro |
| Evidence Level | V |
| Sample | B16F10 melanoma cell line + melanoma-bearing mice |
| Peptide(s) Studied | Melanotan II |
Key Findings
- Paradoxical finding: Topical application of MT-II SUPPRESSED melanoma growth rather than promoting it
- MT-II activated the PTEN tumor suppressor pathway in melanoma cells
- Downstream suppression of AKT phosphorylation, NF-kB activation, and COX-2 expression
- Reduced melanoma cell proliferation, migration, and invasion in vitro
- Topical MT-II reduced tumor volume in melanoma-bearing mice in vivo
- The anti-tumor effect was route-dependent — topical application produced local anti-melanoma effects, contrasting with concerns about systemic MT-II promoting melanocyte proliferation
- Suggests MC1R activation may have context-dependent effects on melanoma depending on signaling context
Study Design
Combined in vitro and in vivo study. In vitro: B16F10 murine melanoma cells treated with MT-II at multiple concentrations; proliferation, migration, invasion assays performed; western blot analysis of PTEN/AKT/NF-kB/COX-2 signaling. In vivo: topical MT-II applied to melanoma implants in mice; tumor volume measured over time.
Limitations
- Murine melanoma cell line (B16F10) may not recapitulate human melanoma biology
- Topical application differs from systemic (SubQ/intranasal) routes used clinically
- Dose-response relationship for anti-tumor effects not fully characterized
- Mechanism may not apply to all melanoma subtypes (BRAF-mutant, NRAS-mutant, etc.)
- Single research group; findings require independent replication
Clinical Relevance
This study presents a paradoxical and intriguing finding: while systemic MT-II raises melanoma safety concerns (case reports in PMID-24355990, PMID-22724573, PMID-40210573), topical MT-II appears to suppress melanoma through PTEN activation. This suggests that the route of administration and local vs. systemic effects may critically determine whether melanocortin activation promotes or suppresses melanocyte transformation. The clinical implication is nuanced — this does not support using MT-II as a melanoma treatment, but it highlights the complexity of melanocortin signaling in cancer biology. Future research should explore whether this pathway can be selectively targeted.
Related
#research #animal-in-vivo #evidence-level-V #cancer